相关实验视频

Updated: Jun 12, 2025

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations

Published on: July 21, 2023

糖尿病前期的微血管并发症:一个系统的审查和元分析

Sama Thiab¹, Taim Akhal¹, Meriem Akeblersane¹

¹School of Medicine, Royal College of Surgeons in Ireland Bahrain, Busaiteen 15503, Bahrain.

Diabetes research and clinical practice

|May 26, 2025

概括

美国糖尿病协会 (ADA) 的糖尿病前期标准 (HbA1c ≥5.7%) 发现的视网膜病变比国际专家委员会 (IEC) 的标准更多. 在糖尿病前期早期检测视网膜病变时,最好采用ADA标准.

科学领域:

内分泌学在内分泌学.
眼科医生眼科眼科
腎臟病學 (nephrology) 是一種醫學專業.

背景情况:

糖尿病前期患病率上升增加了微血管并发症的风险.
在ADA (HbA1c 5.7-6.4%) 和IEC (HbA1c 6.0-6.4%) 的糖尿病前期定义之间存在差异.
确定微血管并发症的最佳糖尿病前查标准至关重要.

研究的目的:

为了确定特定的糖尿病前期血红蛋白A1c (HbA1c) 或禁食血糖 (FBG) 值是否会增加微血管并发症.
为了比较ADA与IEC标准在识别视网膜病变风险方面的有效性.

主要方法:

在主要数据库中对糖尿病前期研究 (1990年至2023年5月) 的系统审查.
包括报告视网膜病变,病变和/或神经病变的研究.
分析了35项研究,其中有21,215项已确定.

主要成果:

与IEC标准相比,ADA标准确定了与IEC标准相比,视网膜病变的流行率和发病率显著更高.
接收器运营商曲线分析显示,在视网膜病变检测IEC标准 (AUC 0.88) 和ADA标准 (AUC 0.73) 中,IEC标准的表现更好.
有限的数据可用于糖尿病前期的脏病和神经病发病率.

结论:

在检测视网膜病变方面,ADA的糖尿病前期标准 (HbA1c 5.7-6.4%) 比IEC标准 (HbA1c 6.0-6.4%) 更敏感.
临床视网膜查可能对HbA1c≥5.7%的个体有益.
需要进一步研究糖尿病前期神经病变和神经病变的患病率.

关键词:

微血管并发症微血管并发症腎病症是指腎病的疾病.神经病变是一种神经病变.糖尿病前期:糖尿病前期.视网膜病变是一种视网膜病变.

更多相关视频

Laser Doppler: A Tool for Measuring Pancreatic Islet Microvascular Vasomotion In Vivo

Laser Doppler: A Tool for Measuring Pancreatic Islet Microvascular Vasomotion In Vivo

Published on: March 8, 2018

Author Spotlight: Understanding Retinal Vessel Resilience and Disease Progression

Author Spotlight: Understanding Retinal Vessel Resilience and Disease Progression

Published on: January 12, 2024

相关概念视频

Diabetes: Symptoms, Diagnosis, and Complications

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

Diabetes Mellitus: Overview and Type I Subtype

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...

Pathophysiology of Diabetes

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...